Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
23 Leser
Artikel bewerten:
(0)

Investigation Report on China's Pranoprofen Market, 2010-2019

DUBLIN, Aug. 28, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/r4hwkk/investigation) has announced the addition of the "Investigation Report on China's Pranoprofen Market, 2010-2019" report to their offering.

Originally discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly known as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen was later developed into eye drop by Senju Pharmaceutical Co., Ltd under the trade name of pranopulin for the treatment of inflammation of outer eye or anterior segment of the eye like blepharitis, conjunctivitis and keratitis. In 1999, pranoprofen eye drops was approved by the CFDA to enter the Chinese market for clinical use, followed by product from Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd in 2009 and product of in 2013.
Pranoprofen developed fast after entering China, with sales value rising from CNY 64.04 million in 2013 to CNY 74.39 million in 2014 with a year-on-year growth of 16.2% and CAGR during the period of 2010-2014 reaching 38.7%.

As computer pervades into work and life, the incidence of eye disease keeps rising, which leads to the vast demand for pranoprofen in China. Currently, pranoprofen in the Chinese market mainly come from the following three enterprises: Senju Pharmaceutical Co., Ltd, Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd, among which Senju Pharmaceutical Co.,Ltd had the largest market share of 89.38% which dropped from 90.59% in 2013 due to Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd's entering into the market with sales reaching CNY 66.49 million in 2014. Domestic drugs are expected to occupy an increasingly large share in the next few years.

Key Topics Covered:

1 Related Concepts of Pranoprofen


2 Market Profile of Pranoprofen in China

3 Survey of Pranoprofen Sales in China, 2010-2014

4 Survey of Major Pranoprofen Manufacturers' Market Share in China, 2010-2014

5 Survey of Dosage Forms of Pranoprofen in China, 2010-2014

6 Reference Price of Pranoprofen in Chinese Hospitals in 2014

7 Major Manufacturers of Pranoprofen in Chinese Market, 2010-2014

8 Market Outlook of Pranoprofen in China, 2015-2019

Companies Mentioned

- Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd
- Senju Pharmaceutical Co., Ltd
- Shandong Haishan Pharmaceutical Co., Ltd

For more information visit http://www.researchandmarkets.com/research/r4hwkk/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.